Quickly sort and find the exact file you need here. Send the files directly into your Shareholder Briefcase or read and right click "save target as" individual files.
| Title |
Type |
Size |
|
| ASCO GI PCI-27483, "Phase I/II study of PCI-27483, a coagulation factor VIIA (FVIIA) inhibitor, in advanced pancreatic cancer patients receiving treatment with gemcitabine." |
|
356.8 KB
|
|
| ASH 2010 PCI-32765 Fowler et al. Oral Presentation,
"The Btk Inhibitor, PCI‐32765, Induces Durable Responses With Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From A Phase I Study" |
|
1.0 MB
|
|
| ASH 2010 PCI-24781 Balasubramanian et al. Poster, "The histone deacetylase (HDAC) inhibitor PCI-24781 decreases pro-inflammatory cytokine secretion in vitro and in vivo, and protects against endotoxemia in a sepsis model" |
|
651.7 KB
|
|
| ASH 2010 PCI-32765 Burger et al. Oral Presentation, "The Bruton's Tyrosine Kinase Inhibitor, PCI‐32765, is Well Tolerated and Demonstrates Promising Clinical Activity in Chronic Lymphomic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL):
An Update on Going Phase 1 Studies" |
|
2.2 MB
|
|
| ASH 2010 PCI-32765 Ponader et al. Oral Presentation, "Bruton's tyrosine kinase inhibitor PCI-32765 abrogates BCR-and nurselike cell-derived activation of CLL cells in vitro and in vivo" |
|
6.7 MB
|
|
| ASH 2010 PCI-32765 Herman et al. Poster, "The Kinase Inhibitor PCI-32765 Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals" |
|
1.6 MB
|
|
| ACR 2010 PCI-45292 Chang et. al. Poster, "PCI-45292, a Novel Btk Inhibitor with Optimized Pharmaceutical Properties, Demonstrates Potent Activities in Rodent Models of Arthritis" |
|
1.8 MB
|
|
|
|
= add file to Briefcase
